AVM Biotechnology’s Post

View organization page for AVM Biotechnology, graphic

2,123 followers

Dr. Deisher will be presenting, at the invitation and sponsorship of the National Cancer Institute, Wednesday 18 Oct 2023 at 10:15 in Franciscan C at the Hilton in San Francisco on Union Square. Dr. Deisher will be available in Franciscan A for additional discussions after her presentation. In 2022 68% of largest pharma new drugs in clinical development for oncology go after targets that are already saturated with approved drugs. Despite enormous advances in precision medicine over the past 2+ decades, cancer deaths declined only 5% between 1997 and 2020. AVM’s lead small molecule targets an immune pathway unique from other immunomodulatory drugs and our patient survival is as good as competitors with 82% grade 1 drug-related side-effects and no grade 4 or 5.

To view or add a comment, sign in

Explore topics